1Northwestern University, Chicago, Illinois.

Replimune's BLA submission and promising pipeline drugs are set to impact the global melanoma therapeutics market. Read more ...

The FDA has received a biologics license application submission for RP1 plus nivolumab in patients with PD-1 ...

BIPAVE-001 is a Phase 1/2 trial designed to evaluate the safety, pharmacokinetic, and efficacy of AI-081. The Part A portion ...

Capivasertib combination shows promise in mHSPC vs the placebo combination, LBS-007 received fast track designation, and RP1 plus nivolumab submitted a BLA application. We also cover a retrospective ...

anti-thymocyte globulins; HLH 2004, treatment protocol for hemophagocytic lymphohistiocytosis; CMV, cytomegalovirus; NGS, next generation sequencing. Image created with biorender.com (accessed on 18 ...

BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally ...

Adagene Inc. (NASDAQ:ADAG – Get Free Report) was the target of a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 1,500 shares, a ...

Cadonilimab plus platinum-based chemotherapy improved progression-free and overall survival in advanced cervical cancer ...

产品活性： Trastuzumab deruxtecan (T-DXd; DS-8201a) 是一种抗人表皮生长因子受体 2 (HER2) 抗体-活性分子偶联物 (ADC)。Trastuzumab deruxtecan 由人源化抗 HER2 ...